# An Clinical Study Evaluating the Safety, Tolerability, and efficAcy of HG005 in StaRgardT Disease

> **NCT07063251** · EARLY_PHASE1 · RECRUITING · sponsor: **HuidaGene Therapeutics Co., Ltd.** · enrollment: 6 (estimated)

## Conditions studied

- Stargardt Disease Type 1 (STGD1)

## Interventions

- **GENETIC:** HG005

## Key facts

- **NCT ID:** NCT07063251
- **Lead sponsor:** HuidaGene Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-20
- **Primary completion:** 2027-02-28
- **Final completion:** 2028-02-28
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2025-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07063251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07063251, "An Clinical Study Evaluating the Safety, Tolerability, and efficAcy of HG005 in StaRgardT Disease". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07063251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*